KHB(SZ:002022)2024-07-09 10:25Financial Performance Expectations - The company expects a net profit loss between 40 million to 57 million CNY for the first half of 2024, compared to a profit of 21.1281 million CNY in the same period last year[7]. - The net profit after deducting non-recurring gains and losses is projected to be a loss between 62 million to 79 million CNY, compared to a profit of 6.8851 million CNY last year[7]. - Basic earnings per share are expected to be a loss between 0.0778 CNY to 0.1108 CNY, compared to a profit of 0.0411 CNY per share in the previous year[7]. - The financial data in the performance forecast has not been audited by registered accountants[8]. Performance Decline Factors - The decline in performance is attributed to market environment changes, intensified industry competition, and the implementation of centralized procurement policies[9]. Strategic Initiatives - The company maintains a high proportion of R&D investment to drive product upgrades and explore new product lines, aiming for comprehensive coverage in the testing field[9]. - The company is focused on a strategy of "comprehensive and precise" and "integrated innovation," aiming to meet national health needs[9]. - Efforts are being made to improve domestic and international sales channels while accelerating overseas market expansion[9]. - The company is implementing lean management to enhance operational efficiency and quality[9]. International Competitiveness - The Italian subsidiary has obtained 57 IVDR certificates in the first half of the year, enhancing international competitiveness[9].